ProHealth me-cfs Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Closer to a Full Understanding of Chronic Fatigue Syndrome

ACTION ALERT: Telling Your Chronic Pain Story Now is Important

Where Is Your Journey Taking You?

Cognition and Chronic Fatigue Syndrome (ME/CFS): Key Findings and Seminal Papers

The Crucial Role CoQ10 Plays in Fibromyalgia and ME/CFS

Living with Purpose

An ME/CFS and FM Recovery Story

SURVEY RESULTS: Should Opioids Be Restricted for Chronic Illness?

Bad Bacteria, Brainstem Abnormalities and Progress with Rituximab: the Invest in ME Conference #1

New FDA Approved Device for Insomnia May Be More Effective Than Drugs

 
Print Page
Email Article

Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome

  [ 1 vote ]   [ Discuss This Article ]
www.ProHealth.com • August 21, 2013


Editor's comment: Cyclobenzaprine is probably best known by the brand name Flexeril, which is currently classified as a muscle relaxant. 

Data Elucidate Cyclobenzaprine as a Serotonin and Norepinephrine Receptor Antagonist and Reuptake Inhibitor (SNARI)

NEW YORK, NY – August 19, 2013 – Tonix Pharmaceuticals Holding Corp. (TNXP), a specialty pharmaceutical company developing novel treatments for challenging disorders of the central nervous system (CNS), including fibromyalgia and post-traumatic stress disorder (PTSD), presented results from nonclinical studies of cyclobenzaprine (CBP), the active ingredient of Tonix's lead candidate, TNX-102 sublingual tablet (TNX-102 SL), at the International Pain Society's Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome in Seattle, Washington.

The presentation, titled "Cyclobenzaprine (CBP) Inhibits Serotonin (5HT) Receptor Type 2A, Adrenergic Receptor alpha1A and the 5HT and Norepinephrine (NE) Reuptake Transporters: Mechanistic Implications for Treating Fibromyalgia Syndrome and Post-traumatic Stress Disorder (PTSD) by Improving Sleep Quality," was given by Bruce Daugherty, Ph.D., Tonix's Chief Scientific Officer and the study's lead author, on Friday, August 16, at 1:45 PM Pacific Time.

As observed in nonclinical studies conducted under Tonix's direction, CBP and its major metabolite, norcyclobenzaprine (nCBP), exhibited potent binding (Ki) to certain CNS receptors including 5HT2A (5.2 and 13 nM, respectively), adrenergic alpha1A (5.6 and 34 nM), and histamine H1 (1.3 and 5.9 nM). In addition, CBP and nCBP are functional antagonists (IC50) at 5HT2A (230 and 140 nM, respectively), alpha1A (4.9 and 16 nM, respectively), and H1 (5.2 and 16 nM, respectively). CBP and nCBP also exhibited potent binding to the serotonin (35 and 2.6 nM, respectively) and norepinephrine (29 and 91 nM, respectively) monoamine reuptake transporters.

Dr. Daugherty commented, "We have significantly advanced our understanding of the mechanisms of action of CBP in the CNS. We have shown that CBP exerts multiple effects on serotonergic and adrenergic neurotransmission. As a Serotonin and Norepinephrine Receptor Antagonist and Reuptake Inhibitor, or SNARI, we believe TNX-102 SL exerts pharmacological effects distinct from those exerted by products approved by the Food and Drug Administration for the management of fibromyalgia and PTSD. We look forward to commencing our Phase 2b/3 trial of TNX-102 SL in patients with fibromyalgia this quarter." 

About Tonix Pharmaceuticals Holding Corp. Tonix is developing innovative prescription medications for challenging disorders of the central nervous system. The Company seeks to address conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among patients and physicians. Tonix's lead pharmaceutical candidate, TNX-102 SL, targets central pain. Fibromyalgia is a central pain syndrome, and central pain is a component of post-traumatic stress disorder. Tonix applies its core technology toward the treatment of central pain by increasing the restorative power of sleep. To learn more, please visit www.tonixpharma.com.

Source: Tonix Pharmaceuticals, Press Release, August 19, 2013.




Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg MitoQ® Mitochondria Ignite™ with NT Factor®

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
Dr Axe Bone Broth Proteins

Featured Products

Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 Your Brain Needs for Detox & Sharpness
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
MitoQ® MitoQ®
Powerful Antioxidant Support to Mitochondria

Natural Remedies

Safely Burn Away Body Fat Safely Burn Away Body Fat
Natural Relief for Soreness, Pain and Swelling – Putting Out the Fire
Strontium - The Missing Mineral for Strong Bones Strontium - The Missing Mineral for Strong Bones
Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask
Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE AND SAVE 15% NOW*
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map